INCY earnings call for the period ending June 30, 2020.
News & Analysis: Incyte
Incyte might finally be convincing Wall Street that its pipeline is the real deal.
INCY earnings call for the period ending March 31, 2020.
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
Is the biotech company worth its rich valuation metrics?
Both diseases involve an overactive immune system.
Here's why Incyte could recover from its poor performance in recent weeks.
The biotech company just reported data from a pair of successful late-stage clinical trials.
Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.